IGF-1 LR3 1mg - 59 € | Lab Peptides France

Name: IGF-1 LR3
Brand: Lab Peptides France
SKU: igf-1-lr3-1mg
Price: 59.00 EUR
Availability: InStock

Zoom

59,00 €

Impuestos incluidos • Entrega gratis desde 99€

+2,95 € en cashback de fidelidad, con una cuenta. Crear mi cuenta

¡Solo quedan 9, vuelan!

Prochain départ : samedi 3 octobre

Stock en Francia

Suscripción

53,10 €-10 %en lugar de 59,00 €

-10 % de por vida en cada cicloPause, salte o cancele en 1 clicSin compromiso, sin gastos ocultos

Tu kit completo

Vial 1mgIncluido
Agua bacteriostáticaAñadir
Jeringas de 1 mlAñadir

El vial por sí solo no puede usarse tal cual. Un vial sellado de IGF-1 LR3 1mg, liofilizado, sin etiquetado individual.

No olvide lo imprescindible

Eau Bactériostatique

7,90 €

Seringue de précision 1ml 29Gx107,90 €

Lingettes alcool isopropylique 70%x103,90 €

Se compran juntos a menudo

GHK-Cu 100mg49,00 €

IGF-1 LR3 (Long R3 Insulin-like Growth Factor 1) is a synthetic analogue of human IGF-1, with 83 amino acids against 70 for the native molecule. Two modifications set it apart: a 13-amino-acid N-terminal extension and the substitution of glutamic acid at position 3 with arginine (hence "R3").

Both changes target the same thing: affinity for the IGFBPs, the six binding proteins that sequester circulating IGF-1. Native IGF-1 is over 95% bound and its free plasma half-life is measured in minutes. The LR3 analogue binds them weakly and stays available far longer — that is the entire rationale for this research version.

This vial delivers 1 mg of IGF-1 LR3 at HPLC purity of at least 98%, lyophilised in type I borosilicate glass. For research use only.

Science

01
Mecanismo de acción

IGF-1 acts on the IGF-1R receptor, a transmembrane tyrosine kinase of the insulin receptor family. Binding triggers receptor autophosphorylation and then two main cascades: the PI3K/Akt/mTOR pathway, associated in the literature with protein synthesis and cell survival, and the MAPK/ERK pathway, associated with proliferation.

What sets LR3 apart is not mechanistic but pharmacokinetic. The IGFBPs, particularly IGFBP-3, form a ternary complex with native IGF-1 that extends its circulating presence while making it unavailable. By reducing that binding, the LR3 analogue increases the free fraction — the amount of molecule actually able to reach the receptor.

Worth noting, as it is a common confusion: reduced IGFBP affinity does not mean increased receptor affinity. LR3 binds IGF-1R with comparable, if slightly lower, affinity than native IGF-1.

Clinical data

02Estudios clínicos

IGF-1 is one of the best-characterised growth factors in the biomedical literature, with several decades of work on its role in growth, glucose metabolism and muscle physiology. Mecasermin, recombinant human IGF-1, holds marketing authorisation for severe primary IGF-1 deficiency, which gives the native molecule a solid pharmacological foundation.

The LR3 analogue, however, was developed and is still overwhelmingly used as a laboratory tool, notably in cell culture where it is widely employed as a medium supplement: its low IGFBP affinity is a direct advantage there, since the binding proteins present in serum would neutralise added native IGF-1.

There is no human clinical trial on IGF-1 LR3, and no authority has evaluated it for therapeutic use. Available data are preclinical, in vitro or animal, and that is the framework in which this product is sold.

Todavía no hay referencias para este péptido: busque en PubMed la literatura científica asociada.

Los estudios enumerados se facilitan únicamente con fines documentales y de investigación. No constituyen una indicación terapéutica ni una recomendación de uso humano. Este producto es estrictamente de uso exclusivo en laboratorio (RUO).

Lab workflow

03
Protocolos de investigación

Reconstitution. The 1 mg vial is reconstituted with 1 ml of bacteriostatic water, giving a 1 mg/ml solution, i.e. 1,000 mcg/ml. On a U-100 insulin syringe, 1 unit then equals 10 mcg, which makes small volumes readable without any calculation.

Procedure: let the vial return to room temperature, disinfect the septum with 70% isopropyl alcohol, inject the water slowly along the inner wall and never directly onto the lyophilised cake, then gently roll the vial between your palms until dissolved. Never shake: the peptide's tertiary structure and its three disulfide bridges are sensitive to it.

On acetic acid. Part of the laboratory literature reconstitutes IGF-1 LR3 in dilute acetic acid (0.6%) for extended storage stability. We do not sell that solvent, and bacteriostatic water is adequate for ordinary use periods; it is a protocol choice, to be documented by the researcher.

Reported orders of magnitude. Research literature typically mentions quantities of 20 to 50 mcg per administration, i.e. 2 to 5 units on a U-100 syringe at this concentration. A 1 mg vial therefore represents 20 to 50 administrations depending on the scheme used. These figures are reported, not recommended.

Reconstitución para este formato (1 mg)Volúmenes estándar utilizados en laboratorio

Agua añadida	Concentración	Marca de lectura
1 ml	1 mg/ml	40 UI = 0,4 mg
2 ml	0,5 mg/ml	40 UI = 0,2 mg

El volumen de agua no cambia el producto, solo su concentración. Introduzca el agua despacio por la pared del vial, nunca directamente sobre el liofilizado, y luego gírelo suavemente sin agitar. Las marcas se dan sobre una jeringa de 1 ml graduada en 100 unidades.

Asepsia

Desinfecte las superficies y los tapones (alcohol al 70%).

Disolvente

Extraiga el volumen necesario de agua bacteriostática.

Introducción

Inyecte suavemente contra la pared del vial (evite el chorro directo sobre el polvo).

Solubilización

Haga rodar el vial suavemente. No lo agite con fuerza (riesgo de degradación).

Conservación de la soluciónUna vez reconstituido: 2-8°C (nevera).

AdvertenciaHerramienta teórica para manipulación química. No constituye un consejo médico.

Abro la calculadora de dilución

Lo que es normal al recibirloLas observaciones que inquietan a los clientes y no son defectos

La cantidad de polvo parece mínima. Un liofilizado ocupa unos pocos milímetros en el fondo del vial, a veces solo una película translúcida. El peso indicado está ahí.
El polvo está compacto, pegado a la pared o al tapón. El transporte desplaza la torta liofilizada. No cambia nada en la reconstitución.
El vial no lleva etiqueta individual. Es nuestro embalaje estándar, no un vial de menor calidad.
Tras la reconstitución aparecen depósitos o filamentos. Es habitual, sobre todo con moléculas pequeñas. Deje que se asiente y haga rodar el vial entre las palmas, nunca lo agite.
El paquete es neutro. Nada en el exterior indica el contenido ni el nombre de la marca.

Lo que no es normal: un vial agrietado, una cápsula sin engastar o un tapón que se mueve, polvo que se ha licuado o cambiado de color. En esos casos concretos, escríbanos con una foto y recuperamos el vial.

Handling

04Conservación y manipulación

Unreconstituted lyophilised vial: stable for several months between 2 and 8 °C, several years in a -20 °C freezer, protected from light. Ambient-temperature transport does not degrade it: the lyophilisate is designed to withstand far more than the duration of a shipment.

After reconstitution: refrigerated between 2 and 8 °C, protected from light. Bacteriostatic water, containing 0.9% benzyl alcohol, allows repeated draws over several weeks. Never freeze a reconstituted solution: a freeze-thaw cycle denatures the peptide even if the solution looks normal afterwards.

A light, uniform haze may appear after reconstitution; it is particles in suspension, a deposit that will not redissolve, or a yellow colour that justify discarding a vial.

01How much water to reconstitute the 1 mg vial?

1 ml of bacteriostatic water, giving 1 mg/ml or 1,000 mcg/ml. On a U-100 syringe, 1 unit then equals 10 mcg: 20 mcg reads as 2 units, 50 mcg as 5 units. It is the most readable concentration for a vial of this size.

02Should I use acetic acid rather than bacteriostatic water?

Part of the laboratory literature uses it, at 0.6%, for long-term storage. We do not sell that solvent. For ordinary use periods, bacteriostatic water is adequate and has the advantage of a preservative allowing repeated draws. It is a protocol choice.

03What is the difference with classic IGF-1?

Availability. Native IGF-1 is over 95% bound by IGFBP transport proteins and its free half-life is measured in minutes. LR3, through its N-terminal extension and Arg3 substitution, binds them weakly and stays available far longer. The target receptor is the same.

04Are there clinical trials on IGF-1 LR3?

No. There is no human clinical trial on IGF-1 LR3, and no authority has evaluated it for therapeutic use. The clinical record belongs to native IGF-1: mecasermin, recombinant human IGF-1, is authorised for severe primary IGF-1 deficiency. LR3 was developed as a laboratory tool and is mainly used as a cell-culture supplement. Its data are preclinical, in vitro or animal, and that is the framework in which this product is sold.

05How many draws does a 1 mg vial represent?

1 mg is 1,000 mcg. At the quantities reported in the literature, 20 to 50 mcg per administration, a vial therefore represents 20 to 50 draws. Actual autonomy depends entirely on the scheme chosen by the researcher.

06Can it be combined with a secretagogue such as CJC-1295 or Ipamorelin?

These are two different levels of action: secretagogues stimulate growth hormone release upstream, IGF-1 LR3 acts downstream on the receptor. Research literature documents both separately and we do not offer a combined protocol, which is not established.

07Must the solution be perfectly clear?

A light, uniform haze may appear and is not a defect. What justifies discarding a vial is particles that stay in suspension, a deposit that will not redissolve despite cold rest, or a yellow colour.

Benchmark

Péptidos similares

Against native IGF-1 (mecasermin). Same receptor, same cascade, but incomparable availability: native IGF-1 is over 95% sequestered by IGFBPs, LR3 largely escapes them. That is the only difference that matters in practice, and it is pharmacokinetic.

Against secretagogues (Ipamorelin, CJC-1295, Tesamorelin). The difference is one of level. Secretagogues act upstream: they stimulate the pituitary to release growth hormone, which then drives hepatic IGF-1 production. They therefore preserve physiological pulsatility and feedback loops. IGF-1 LR3 bypasses that chain and acts downstream, directly on the receptor. The two approaches are not interchangeable and are not documented in the same way.

Against MGF and PEG-MGF. MGF is a splice isoform of IGF-1, with a different E domain and local action; its pegylated form seeks to extend a naturally very short half-life. These are neighbouring but distinct molecules, with separate literatures.

IGF-1 LR3 1mg Crecimiento Muscular

Factores de crecimiento

01
Mecanismo de acción

02Estudios clínicos

03
Protocolos de investigación

Asepsia

Disolvente

Introducción

Solubilización

04Conservación y manipulación

Péptidos similares

Factores de crecimiento

Información del producto

Asepsia

Disolvente

Introducción

Solubilización

Reactivos complementarios